Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma

Ítems similars

• Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma
  per: Peters, Katherine B., et al.
  Publicat: (2015)
• The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide and Irinotecan for Newly Diagnosed Glioblastoma
  per: Vredenburgh, James J., et al.
  Publicat: (2011)
• Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients
  per: Reardon, David A., et al.
  Publicat: (2011)
• AT-22 PHASE II TRIAL OF BEVACIZUMAB, RADIATION THERAPY (RT) AND TEMOZOLOMIDE FOLLOWED BY BEVACIZUMAB AND TEMOZOLOMIDE WITH CONTINUATION OF BEVACIZUMAB BEYOND PROGRESSION
  per: Ghiaseddin, Ashley, et al.
  Publicat: (2014)
• Phase II study of carboplatin, irinotecan and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
  per: Reardon, David A., et al.
  Publicat: (2011)